Medicine · 9 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
In a retrospective cohort study of elderly (>40 years) osteosarcoma patients, the fibrinogen-albumin ratio (FAR) above 0.098 was identified as an independent risk factor for worse overall survival, alongside metastasis and pathological fracture.
This retrospective cohort study evaluated the prognostic value of the fibrinogen-albumin ratio (FAR) in elderly patients (>40 years) with osteosarcoma. Clinical-pathological characteristics, including age, tumor size, tumor stage, recurrence, and metastasis, were assessed in relation to FAR. The cutoff value of FAR for overall survival was determined to be 0.098. Elderly osteosarcoma patients with FAR higher than 0.098 had poorer overall survival compared with patients with low FAR. The 5-year overall survival rate in this cohort was 58.5%. A nomogram integrating metastasis, pathological fracture, and FAR was developed. Limitations include the retrospective design, relatively small sample size, long time-span of included cases, lack of a validation cohort, and cohort-dependent cutoff values.
